Tags · Evidence
randomised trial
Randomised controlled trial evidence.
Related in this group: STEP programme · SURMOUNT programme · SURPASS programme · SELECT trial · FLOW trial · SOUL trial · TRIUMPH programme · PIONEER programme · SUSTAIN programme · LEADER trial · meta-analysis · observational data
174 topics · page 6 of 6
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
SNAC and the mechanism of oral peptide absorption — the long version
SNAC and the mechanism of oral peptide absorption — the long version Writing it up because I had to work it out twice and would rather nobody else did. Question about what the published evidence for this…
|
+32 | 36 | 6.8k | 16mo |
|
Retatrutide's phase 2 heart-rate signal and how to think about it — the long version
Retatrutide's phase 2 heart-rate signal and how to think about it — the long version Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post,…
|
2 | 103 | 17mo | |
|
SNAC and the mechanism of oral peptide absorption
On the subject in the title: SNAC and the mechanism of oral peptide absorption Working notes rather than a conclusion. A comparison question rather than a question about one compound. Two things in the same…
|
+13 | 17 | 14k | 17mo |
|
[2026 update] Journal club: SURPASS-2 and the semaglutide 1 mg comparator
Journal club: SURPASS-2 and the semaglutide 1 mg comparator Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it…
|
+126 | 138 | 31k | 17mo |
|
Semaglutide in people without diabetes: what the evidence base looks like
Semaglutide in people without diabetes: what the evidence base looks like Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of semaglutide…
|
+2 | 6 | 18k | 17mo |
|
Amylin and gastric emptying: overlapping mechanisms with incretins
On the subject in the title: Amylin and gastric emptying: overlapping mechanisms with incretins Working notes rather than a conclusion. Posting a small dataset on amylin and gastric emptying. It is mine, it…
|
2 | 50k | 17mo | |
|
Reading a supplementary appendix and finding the interesting part
Reading a supplementary appendix and finding the interesting part — setting out what I have, and where I think it stops being reliable. Collecting what is known about reading a supplementary appendix in one…
|
+87 | 92 | 1.1k | 17mo |
|
Second pass at: Historical amylin analogues and what happened to them
Second pass at: Historical amylin analogues and what happened to them — setting out what I have, and where I think it stops being reliable. The question about Historical amylin analogues that I actually want…
|
+15 | 19 | 22k | 18mo |
|
SURPASS-2 and the comparator dose question that will not go away
SURPASS-2 and the comparator dose question that will not go away — setting out what I have, and where I think it stops being reliable. A methods question rather than a substantive one, about SURPASS-2.…
|
+101 | 111 | 1.5k | 18mo |
|
Dose numbers for oral formulations are not comparable to injectable ones — a second dataset
Dose numbers for oral formulations are not comparable to injectable ones — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on Dose…
|
+48 | 52 | 59k | 18mo |
|
Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide
Posting this under the heading it deserves: Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Everything below is what sits behind that. I have spent a fortnight trying…
|
+72 | 77 | 7.2k | 19mo |
|
Oral semaglutide bioavailability and its variability between people — a second dataset
Oral semaglutide bioavailability and its variability between people — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Oral semaglutide…
|
+141 | 154 | 47k | 19mo |
|
Molecular mass of semaglutide and why the figure differs between sources — does this still hold?
Molecular mass of semaglutide and why the figure differs between sources — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in…
|
+94 | 102 | 14k | 19mo |
|
Follow-up: Semaglutide versus liraglutide head to head: reading STEP 8 carefully
Semaglutide versus liraglutide head to head: reading STEP 8 carefully — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on…
|
+1 | 5 | 11k | 20mo |
|
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold?
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Practical question…
|
+58 | 62 | 49k | 20mo |
|
[2026 update] Comparing tirzepatide and semaglutide is harder than the tables suggest
Comparing tirzepatide and semaglutide is harder than the tables suggest Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post, because a…
|
2 | 23k | 21mo | |
|
Journal club: SURPASS-2 and the semaglutide 1 mg comparator
On the subject in the title: Journal club: SURPASS-2 and the semaglutide 1 mg comparator Working notes rather than a conclusion. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it before posting;…
|
+71 | 76 | 52k | 21mo |
|
Hepatic effects of glucagon receptor agonism: the mechanistic worry
Posting this under the heading it deserves: Hepatic effects of glucagon receptor agonism: the mechanistic worry Everything below is what sits behind that. Something about hepatic effects of glucagon receptor…
|
+51 | 56 | 700 | 22mo |
|
The C-cell question: rodent findings and their human context — what changed since
The C-cell question: rodent findings and their human context — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of c-cell question…
|
+61 | 65 | 1.3k | 22mo |
|
About the Retatrutide category
Triple GIP/GLP-1/glucagon receptor agonist. Phase 2 data, TRIUMPH programme, and cautious practical discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…
|
4 | 12k | 2y | |
|
The most common factual error about semaglutide on the internet
On the subject in the title: The most common factual error about semaglutide on the internet Working notes rather than a conclusion. Putting the numbers in the first post, because a question about a compound…
|
2 | 49k | 2y | |
|
Second pass at: Journal club: LEADER as the historical anchor
Posting this under the heading it deserves: Second pass at: Journal club: LEADER as the historical anchor Everything below is what sits behind that. Two things I would like separated before anyone answers on…
|
+75 | 81 | 2k | 2y |
|
Second pass at: Retatrutide dose escalation in the published trials
Second pass at: Retatrutide dose escalation in the published trials — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on Retatrutide…
|
+115 | 125 | 30k | 2y |
|
Journal club: FLOW and the renal composite, component by component
On the subject in the title: Journal club: FLOW and the renal composite, component by component Working notes rather than a conclusion. Reading FLOW ( N Engl J Med , 2024) for the population rather than the…
|
+84 | 91 | 18k | 2y |